Star Sports Medicine Jumps 204% in Hong Kong Debut as IPO Demand Runs Hot

Star Sports Medicine Co. surged as much as 204% in its Hong Kong trading debut on May 5, extending a run of intense demand for new listings in the city, according to Bloomberg. The medical-device and sports-medicine company traded as high as HK$299 early in the session, compared with its HK$98.50 IPO price, Bloomberg reported.

The Details

Bloomberg reported that Star Sports Medicine raised HK$829.6 million in the offering and that the retail portion was subscribed more than 7,823 times. The figures point to heavy investor demand around the company's listing, with the first-day share move turning that demand into one of the sharpest debut pops in Hong Kong's recent IPO run.

The company's official HKEX prospectus set the offer price at HK$98.50 per H share and listed 8,421,850 H shares under stock code 1609. The prospectus said trading was scheduled to begin on May 5, matching the debut date reported by Bloomberg.

Star Sports Medicine is a medical-device maker focused on sports medicine products, including medical implants and surgical equipment, according to Bloomberg and Bamboo Works. That business profile places the company in a specialized healthcare equipment segment rather than a consumer sports brand, even though its name centers on sports medicine.

The pricing and share-count record also matters because one earlier report carried a different fundraising figure. Bamboo Works said the IPO aimed to raise HK$758 million by selling about 8.4 million shares at HK$98.50 each, while the HKEX prospectus listed 8,421,850 offer shares and Bloomberg later reported HK$829.6 million raised. For that reason, the prospectus and Bloomberg figures are the clearest figures to use for the completed deal.

Bamboo Works reported that four cornerstone investors agreed to buy 34.7% of the shares sold in the IPO. That cornerstone participation sat alongside the wider retail demand later reported by Bloomberg, which said the retail tranche was subscribed more than 7,823 times.

The Standard reported that Star Sports Medicine was up more than 500% in gray-market trading before its formal debut. That pre-listing move gave an early signal of frothy demand before the shares began official trading, according to The Standard.

Finimize separately characterized the Star Sports Medicine IPO as drawing huge demand. Its description reinforced the demand narrative reported by Bloomberg, The Standard and Bamboo Works, while Bloomberg's first-day trading data provided the clearest measure of the stock's formal market debut.

Context

Star Sports Medicine's debut came during a broader rebound in Hong Kong's new-listing market, according to Reuters. Reuters reported that Victory Giant Technology, another recent Hong Kong IPO, closed 50.1% above its offer price on debut after raising HK$20.1 billion.

That comparison does not make the two listings identical, but it places Star Sports Medicine's first-day surge inside a wider run of strong Hong Kong IPO performances reported by major financial outlets. Bloomberg framed Star Sports Medicine's 204% rise as an extension of the city's debut frenzy, while Reuters described Victory Giant's prior first-day gain as part of a broader rebound in new listings.

The Star Sports Medicine listing also shows how demand appeared across several points in the offering process, based on the briefed source record. Bamboo Works reported cornerstone-investor commitments, The Standard reported a large gray-market advance, and Bloomberg reported the heavy retail subscription level and formal first-day trading jump.

What's Next

The immediate next step is continued public trading of Star Sports Medicine's H shares on the Hong Kong market under stock code 1609, according to the HKEX prospectus. Bloomberg's debut data, including the HK$299 early-session high and the HK$98.50 offer price, gives investors the first formal trading reference point after the IPO.

The fundraising record should continue to be read against the official prospectus and Bloomberg's completed-deal figure. Bamboo Works' earlier HK$758 million figure is part of the sourcing record, but the HKEX share count and Bloomberg's HK$829.6 million raised are the figures supported by the official listing document and the later market report.

For Hong Kong's IPO market, the next comparable signals will come from other new listings and their first-day trading results. Reuters' report on Victory Giant Technology and Bloomberg's report on Star Sports Medicine provide two recent examples of strong debut demand in the city.